Molecular Templates Announces Executive Leadership Changes
2023年8月3日 - 5:11AM
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular
Templates,” or “MTEM”), a clinical-stage biopharmaceutical company
developing novel therapeutics for oncology with potent
differentiated mechanisms of action, today announced executive
management changes to implement its next phase of development. Dr.
Gabriela Gruia will assume the role of interim Chief Medical
Officer to succeed Dr. Roger Waltzman, Jason Kim will assume the
role of President and Chief Financial Officer, Kristen Quigley will
assume the role of Chief Operating Officer, and Dr. Grace Kim will
assume the role of Chief Strategy Officer and Head of Investor
Relations. These appointments were made to better enable Molecular
Templates to execute on its clinical and corporate objectives.
Dr. Gabriela Gruia joined Molecular Templates in 2022 as a Board
Director for MTEM. She has over 25 years of experience in oncology
drug development. Dr. Gruia previously served as Chief Development
Officer at Ichnos Sciences. Prior to Ichnos Sciences, Dr. Gruia was
Senior Vice President and Global Head of Regulatory Affairs for
Novartis Oncology. Prior to that, she held oncology clinical
research and development roles at Pfizer/Pharmacia,
Aventis/Rhone Poulenc Rorer. Dr. Gruia earned a doctorate in
medicine from Bucharest Medical School in Romania. She
completed training in oncology and hematology at Rene Descartes
University in Paris, France and a Masters in Breast Pathology
and Mammography from the Rene Huguenin/Curie Institute Cancer
Center in Paris, France. The Company has initiated a search
for a permanent Chief Medical Officer. Dr. Gruia will remain a
Board Director for MTEM.
Jason Kim joined Molecular Templates in 2010 and serves as
President and previous Chief Operating Officer. He also served as
Molecular Templates’ President and Chief Financial Officer from
February 2010 to August 2017. Previously, Mr. Kim led corporate
development and strategic planning initiatives at OSI
Pharmaceuticals and ImClone Systems. He served as an investment
professional at Domain Associates and Safeguard Scientifics where
he focused on venture and public investments in biotechnology. Mr.
Kim holds a Master of Business Administration from The Wharton
School and a Bachelor of Arts in Neuroscience from Wesleyan
University.
Kristen Quigley joined Molecular Templates in 2017 and
previously served as Senior Vice President of Clinical Operations.
She has 27 years of clinical research experience, including 24
years in phase I-IV clinical trial and project management, and over
6 years in executive roles. Kristen served in Vice President/
Senior Vice President of Clinical Operations roles at two biotech
companies prior to joining Molecular Templates, she co-directed the
Nordic region for a large global CRO, and she has successfully
governed clinical development portfolios worth as much as $147M.
Ms. Quigley holds a Bachelor of Arts in Psychology from Washington
University in St. Louis.
Dr. Grace Kim joined Molecular Templates in 2022
with 20 years of experience driving investor strategy, corporate
strategy, and business development. Previously, she led two
biopharma advisories in Senior Vice President and Founder roles and
served on matrixed leadership teams. Companies she worked with
include BeiGene, BioMarin, Cullinan Oncology, Celularity, Aimmune
(Nestlé), and others. Dr. Kim earned a doctorate in pharmacology
from the University of Florida with post-doc immunology training
and graduate studies at the University of Chicago. She is published
in Nature Clinical Oncology and holds an adjunct faculty position
at Columbia University.
“We thank Roger for all his hard work in advancing
our compounds in the clinic. We are now at an exciting inflection
point at MTEM. We have seen evidence of monotherapy activity during
dose escalation with our ETBs and now look to define the rate of
activity in dose expansion studies with these agents over the next
12 months. These management changes will help enable us to execute
efficiently in the clinic and in our corporate goals,” said Eric
Poma, PhD., Chief Executive and Chief Scientific Officer of
Molecular Templates.
About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical
company focused on the discovery and development of targeted
biologic therapeutics. Our proprietary drug platform technology,
known as engineered toxin bodies, or ETBs, leverages the resident
biology of a genetically engineered form of Shiga-like Toxin A
subunit to create novel therapies with potent and differentiated
mechanisms of action for cancer.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995
(the “Act”). Molecular Templates disclaims any intent or obligation
to update these forward-looking statements and claims the
protection of the Act’s Safe Harbor for forward-looking statements.
All statements, other than statements of historical facts, included
in this press release, including, but not limited to those
regarding strategy, inflection points, future operations, the
Company’s ability to execute on its objectives, prospects, plans,
future execution of corporate goals, and the skills and experiences
of the newly appointed officers of Molecular Templates and
expectations with respect to their future contributions to the
Company and statements, evaluations and judgements regarding future
clinical development of the Company’s product candidates, including
any implication that results or observations in earlier clinical
trials will be representative of results or observations in later
clinical trials and the expected timing of such results. In
addition, when or if used in this press release, the words “may,”
“could,” “should,” “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “plan,” “predict” and similar expressions and their
variants, as they relate to Molecular Templates may identify
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties. Actual events or results may differ materially from
those discussed in the forward-looking statements as a result of
various factors including, but not limited to the following: the
continued availability of financing on commercially reasonable
terms, whether Molecular Templates’ cash resources will be
sufficient to fund its continuing operations; the results of MTEM’s
ongoing clinical studies and its collaboration activities with BMS,
the ability to effectively operate MTEM and retain key employees
post-MTEM’s previously announced restructuring, the ability of MTEM
to maintain the continued listing of its common stock on Nasdaq,
and those risks identified under the heading “Risk Factors” in
Molecular Templates’ filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023 and any subsequent reports filed with
the Securities and Exchange Commission. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Molecular Templates specifically disclaims any
obligation to update any forward-looking statement, whether because
of new information, future events or otherwise.
Contacts:Grace Kim grace.kim@mtem.com
Molecular Templates (NASDAQ:MTEM)
過去 株価チャート
から 11 2024 まで 12 2024
Molecular Templates (NASDAQ:MTEM)
過去 株価チャート
から 12 2023 まで 12 2024